Sustained Oligomycin Sensitivity Conferring Protein Expression in Cardiomyocytes Protects Against Cardiac hypertrophy...

Area of Science:

• Cardiology
• Mitochondrial Biology
• Gene Therapy

Background:

• Cardiac hypertrophy is a significant risk factor for heart failure, associated with high morbidity and mortality.
• Mitochondrial dysfunction is a key feature of cardiac hypertrophy and heart failure.
• Oligomycin sensitivity conferring protein (OSCP) is crucial for mitochondrial energy production via F1Fo-ATP synthase.

Purpose of the Study:

• To investigate the role of OSCP in cardiac hypertrophy.
• To evaluate the therapeutic potential of OSCP gene therapy in a mouse model of cardiac hypertrophy.

Main Methods:

• Cardiac-specific gene therapy using adeno-associated virus (AAV) to overexpress OSCP in mice subjected to transverse aortic constriction (TAC).
• Assessment of cardiac function, cardiomyocyte size, fibrosis, mitochondrial respiration, reactive oxygen species (ROS) production, and mitochondrial permeability transition pore (mPTP) opening.

Main Results:

• Impaired cardiac OSCP expression correlated with mitochondrial dysfunction in hypertrophied hearts.
• OSCP gene therapy significantly protected against TAC-induced cardiac dysfunction, cardiomyocyte hypertrophy, and fibrosis.
• OSCP therapy enhanced mitochondrial respiration and reduced ROS production and mPTP opening in hypertrophied hearts.

Conclusions:

• Cardiac-specific AAV-mediated OSCP overexpression improves mitochondrial function.
• OSCP gene therapy demonstrates a protective effect against cardiac hypertrophy and dysfunction.
• This approach offers a potential novel therapeutic strategy for cardiac hypertrophy and heart failure.